Intra-Cellular Therapies
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 610
- Market Cap
- $7.8B
- Introduction
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate,...
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT06706674
- Locations
- 🇺🇸
Clinical Site, Everett, Washington, United States
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 570
- Registration Number
- NCT06701903
- Locations
- 🇺🇸
Clinical Site, Bellevue, Washington, United States
🇺🇸Cinical Site, Orlando, Florida, United States
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT06690398
- Locations
- 🇺🇸
Clinical Site, Bellevue, Washington, United States
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT06651567
- Locations
- 🇺🇸
Clinical Site, Round Rock, Texas, United States
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06627413
- Locations
- 🇺🇸
Clinical Site 2, Los Alamitos, California, United States
🇺🇸Clinical Site 3, Atlanta, Georgia, United States
🇺🇸Clinical Site 4, Decatur, Georgia, United States
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT06557902
- Locations
- 🇺🇸
Clinical Site 6, Miami, Florida, United States
🇺🇸Clinical Site 1, Atlanta, Georgia, United States
🇺🇸Clinical Site 4, Saint Charles, Missouri, United States
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 370
- Registration Number
- NCT06540833
- Locations
- 🇺🇸
Clinical Site, Toms River, New Jersey, United States
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 705
- Registration Number
- NCT06480383
- Locations
- 🇺🇸
Clinical SIte, DeSoto, Texas, United States
🇺🇸Clinical Site, Bellevue, Washington, United States
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT06462612
- Locations
- 🇺🇸
Clinical Site, Richardson, Texas, United States
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT06462586
- Locations
- 🇺🇸
Clinical Site, DeSoto, Texas, United States